RayKnowChina Research Map
Shortlist0

Lanzhou

Lanzhou University Second Hospital

兰州大学第二医院

Listed for 19 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

Official links opened and checked on 2026-11-08.

Getting in touch

Research at Lanzhou University Second Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Oesophageal squamous cell carcinoma食管鳞状细胞癌10 papers led
  2. Hepatocellular carcinoma肝细胞癌45 papers led
  3. Stomach cancer胃癌108 papers led
  4. Chordoma脊索瘤1 paper led
  5. Osteosarcoma骨肉瘤15 papers led
  6. Gastrointestinal stromal tumour胃肠道间质瘤5 papers led
  7. Neuroblastoma神经母细胞瘤2 papers led
  8. Ewing sarcoma尤文肉瘤2 papers led
  9. Multiple myeloma多发性骨髓瘤12 papers led
  10. IgG4-related diseaseIgG4相关性疾病2 papers led
  11. Myasthenia gravis重症肌无力2 papers led
  12. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎2 papers led
  13. Takayasu arteritis大动脉炎0 papers led
  14. Idiopathic pulmonary fibrosis特发性肺纤维化0 papers led
  15. Duchenne muscular dystrophy杜氏肌营养不良1 paper led
  16. IgA nephropathyIgA 肾病2 papers led
  17. Gaucher disease戈谢病0 papers led
  18. Primary biliary cholangitis原发性胆汁性胆管炎0 papers led
  19. Primary sclerosing cholangitis原发性硬化性胆管炎1 paper led

Not listed for: Nasopharyngeal carcinoma, Hepatoblastoma, Retinoblastoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, Moyamoya disease, Wilson disease, Biliary atresia, Hepatic echinococcosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Behçet disease, Alport syndrome, Niemann–Pick disease type C, Osteogenesis imperfecta, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 10 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
10
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 3320222023: 2220232024: 1120242025: 222025

3 hospitals in Lanzhou for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesNeoadjuvant & combined treatmentMolecular markers & genomicsImaging & AI
Departments in papersMedical oncologyRadiology / nuclear medicine

Over half of these papers are lab or animal studies.

Papers it led10
  1. Predictive value of 18F-FDG PET/CT-based radiomics model for lymph node metastasis in esophageal squamous cell carcinoma.2026Annals of nuclear medicine
  2. BRD4 Induces Esophageal Squamous Cell Carcinoma Progression via the Wnt/β-catenin Pathway.2026Biochemical geneticsFree full text
  3. Neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell carcinoma: a retrospective study with 2-year survival analysis.2025Journal of cancer research and clinical oncologyFree full text
  4. PYCR1 Promotes Esophageal Squamous Cell Carcinoma by Interacting With EGFR to Affecting the PI3K/Akt/mTOR Signaling Pathway.2025The journal of gene medicine
  5. Downregulation of ALDH5A1 suppresses cisplatin resistance in esophageal squamous cell carcinoma by regulating ferroptosis signaling pathways.2024Molecular carcinogenesis
  6. Utility of near-infrared fluorescence imaging with indocyanine green in resection of oesophageal squamous cell carcinoma: A literature review and a case report.2023Photodiagnosis and photodynamic therapy
  7. Molecular mechanism underlying epithelial-mesenchymal transformation and cisplatin resistance in esophageal squamous cell carcinoma.2023Thoracic cancerFree full text
  8. Epithelial-Mesenchymal Transition Gene Signature Is Associated with Neoadjuvant Chemoradiotherapy Resistance and Prognosis of Esophageal Squamous Cell Carcinoma.2022Disease markersFree full text
  9. Long non‑coding RNA PART1: dual role in cancer.2022Human cell
  10. SYNGR2 serves as a prognostic biomarker and correlates with immune infiltrates in esophageal squamous cell carcinoma.2022The journal of gene medicine
All its trials on ClinicalTrials.gov, any status2
  1. A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT06010303Study sitePhase 2Start 2023-11
  2. Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT04732494Study sitePhase 2Start 2021-03
More papers found outside PubMed (not counted)1
  1. Chemotherapy plus camrelizumab versus chemotherapy alone as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (ESCORT-NEO): A multi-center, randomized phase III trial.2024Journal of Clinical Oncologyconference-abstract

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 45 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
45
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 4420212022: 7720222023: 101020232024: 7720242025: 15152025

2 hospitals in Lanzhou for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    Phase
    Phase 3
    Started
    2023-05
    Registry
    NCT05862337

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 43 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Lanzhou, Luzhou, Nanchang, Nanchong, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Taizhou, Tianjin, Urumqi, Wenzhou, Xi'an, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImaging, AI & early detectionImmunotherapy & targeted drugs
Departments in papersSurgery (general/hepatobiliary/pancreatic)Pathology / laboratory medicineRadiology / nuclear medicineMedical oncology
Papers it led45
  1. Whole-lesion iodine map histogram analysis combined with focal ROI iodine concentrations for preoperative prediction of cytokeratin 19-positive hepatocellular carcinoma.2026Abdominal radiology (New York)
  2. Deep learning 3D super-resolution radiomics model based on Gd-enhanced MRI for improving preoperative prediction of HCC pathological grading.2026Abdominal radiology (New York)
  3. Prediction of Posthepatectomy Liver Failure in Narrow Resection Margins HCC: A Model Based on Iodine Map Histogram Analysis of Nontumorous Liver Parenchyma.2025Academic radiology
  4. Comprehensive molecular characteristics of hepatocellular carcinoma based on multi-omics analysis.2025BMC cancerFree full text
  5. Visit‑to‑visit variability of inflammation-immunity indices and prognosis in hepatocellular carcinoma.2025BMC gastroenterologyFree full text
  6. Adherence to STARD guidelines in miRNA diagnostic accuracy studies for hepatocellular carcinoma: a systematic review.2025BMC medical research methodologyFree full text
  7. Study on the concordance in the diagnostic efficacy between CEUS LI-RADS and CT/MR LI-RADS for HCC.2025Clinical hemorheology and microcirculation
  8. Breaking bottlenecks: the future of hepatocellular carcinoma clinical trials and therapeutic targets.2025Hepatology international
  9. APM-Related gene signature model to predict prognosis and immunotherapy response in hepatocellular carcinoma.2025Human genetics
  10. Therapeutic targets for hepatocellular carcinoma identified using proteomics and Mendelian randomization.2025Journal of gastroenterology and hepatology
  11. A spreadable self-gelling hemostatic powder sensitizes CAR-NK cell therapy to prevent hepatocellular carcinoma recurrence postresection.2025Journal of nanobiotechnologyFree full text
  12. Post-translational modifications in hepatocellular carcinoma: mechanisms and therapeutic potential.2025Medical oncology (Northwood, London, England)
  13. Causal relationship between serum bilirubin, cholelithiasis and hepatobiliary and pancreatic malignancy: A bidirectional and 2-sample Mendelian randomization study.2025MedicineFree full text
  14. A contrast‑enhanced CT histogram‑driven nomogram for predicting post‑radiotherapy liver regeneration in hepatocellular carcinoma.2025Radiation oncology (London, England)Free full text
  15. Integrating single-cell RNA sequencing, WGCNA, and machine learning to identify key biomarkers in hepatocellular carcinoma.2025Scientific reportsFree full text
  16. Progress of Pyruvate Kinase M2 in Hepatocellular Carcinoma-Associated Signaling Pathway.2025Tissue engineering. Part C, Methods
  17. P2RX4 promotes hepatocellular carcinoma progression via calcium-mediated PI3K/AKT activation and immune remodeling.2025World journal of surgical oncologyFree full text
  18. Alpha-fetoprotein upregulates hepatocellular carcinoma cell-intrinsic PD-1 expression through the LATS2/YAP/TEAD1 pathway.2024Biochimica et biophysica acta. General subjects
  19. The Role of Pyruvate Kinase M2 Posttranslational Modification in the Occurrence and Development of Hepatocellular Carcinoma.2024Cell biochemistry and function
  20. FXa-mediated PAR-2 promotes the efficacy of immunotherapy for hepatocellular carcinoma through immune escape and anoikis resistance by inducing PD-L1 transcription.2024Journal for immunotherapy of cancerFree full text
  21. Prognostic Significance of Iron Metabolism and Immune-Related Genes as Risk Markers in Hepatocellular Carcinoma.2024Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer
  22. Integrative analysis of multi-omics data identified PLG as key gene related to Anoikis resistance and immune phenotypes in hepatocellular carcinoma.2024Journal of translational medicineFree full text
  23. Transarterial Chemoembolization Combined with Lenvatinib for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2024Oncology
  24. Identification and verification of a prognostic autophagy-related gene signature in hepatocellular carcinoma.2024Scientific reportsFree full text
  25. Different power modes of microwave ablation for hepatocellular carcinoma: Evaluation of recurrence rate and factors related to recurrence.2023Asian journal of surgery
  26. Development and validation of a coagulation-related genes prognostic model for hepatocellular carcinoma.2023BMC bioinformaticsFree full text
  27. MicroRNA-5195-3p mediated malignant biological behaviour of insulin-resistant liver cancer cells via SOX9 and TPM4.2023BMC cancerFree full text
  28. Predicting glypican-3 expression in hepatocellular carcinoma: A comprehensive analysis using combined contrast-enhanced ultrasound and clinical factors.2023Clinical hemorheology and microcirculation
  29. Neutrophil extracellular traps regulating tumorimmunity in hepatocellular carcinoma.2023Frontiers in immunologyFree full text
  30. Establishment and characterization of a new Chinese hepatocellular carcinoma cell line, Hep-X1.2023Human cell
  31. PA-MSHA Regulates PD-L1 Expression in Hepatoma Cells.2023Immunological investigations
  32. Predictive Roles of ADAM17 in Patient Survival and Immune Cell Infiltration in Hepatocellular Carcinoma.2023International journal of molecular sciencesFree full text
  33. RPS24 Is Associated with a Poor Prognosis and Immune Infiltration in Hepatocellular Carcinoma.2023International journal of molecular sciencesFree full text
  34. Contrast-enhanced ultrasound demonstrates greater adjuvant potential: past, current status, and future applications in Hepatocellular carcinoma early diagnosis.2023Medical ultrasonography
  35. BUB1 predicts poor prognosis and immune status in liver hepatocellular carcinoma.2022APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  36. Study on correlation between two-dimensional ultrasound, contrast-enhanced ultrasound and microvascular invasion in hepatocellular carcinoma.2022Clinical hemorheology and microcirculation
  37. Overexpression of Ribosomal Protein S6 Kinase A4 (RPS6KA4) Predicts a Poor Prognosis in Hepatocellular Carcinoma Patients: A Study Based on TCGA Samples.2022Combinatorial chemistry & high throughput screening
  38. Relationship between Intestinal Microflora and Hepatocellular Cancer Based on Gut-Liver Axis Theory.2022Contrast media & molecular imagingFree full text
  39. The effect of metformin usage on survival outcomes for hepatocellular carcinoma patients with type 2 diabetes mellitus after curative therapy.2022Frontiers in endocrinologyFree full text
  40. Anticancer Effect of Arbutin on Diethylnitrosamine-Induced Liver Carcinoma in Rats via the GRP and GADD Pathway.2022Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer
  41. Overexpressed PAQR4 predicts poor overall survival and construction of a prognostic nomogram based on PAQR family for hepatocellular carcinoma.2022Mathematical biosciences and engineering : MBE
  42. Bioinformatic Evidence Reveals that Cell Cycle Correlated Genes Drive the Communication between Tumor Cells and the Tumor Microenvironment and Impact the Outcomes of Hepatocellular Carcinoma.2021BioMed research internationalFree full text
  43. The lncRNA VPS9D1-AS1 Promotes Hepatocellular Carcinoma Cell Cycle Progression by Regulating the HuR/CDK4 Axis.2021DNA and cell biology
  44. The expression and clinical significance of TPM4 in hepatocellular carcinoma.2021International journal of medical sciencesFree full text
  45. Transcript levels of spindle and kinetochore-associated complex 1/3 as prognostic biomarkers correlated with immune infiltrates in hepatocellular carcinoma.2021Scientific reportsFree full text
Chinese-language papers (not in the count)1
  1. [Overexpression of Nei endonuclease VIII-like protein 3 in hepatocellular carcinoma indicates increased levels of immune infiltration and an unfavorable prognosis].2023Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
All its trials on ClinicalTrials.gov, any status2
  1. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.RecruitingNCT05862337Study sitePhase 3Start 2023-05
  2. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)Active, not recruitingNCT04344158Study sitePhase 3Start 2020-08

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 108 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 1.1%.

Papers led
108
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
4
led by another institution
Papers led per year
2021: 121220212022: 151520222023: 202020232024: 202020242025: 38382025

3 hospitals in Lanzhou for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 4

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
    Phase
    Phase 3
    Started
    2025-02
    Registry
    NCT06731478

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changzhou, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Linyi, Shanghai, Shenyang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yinchuan, Zhengzhou

  2. Recruiting
    Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
    Phase
    Phase 3
    Started
    2025-04
    Registry
    NCT06925243

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesGuangzhou, Lanzhou

  3. Recruiting
    Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
    Phase
    Phase 3
    Started
    2025-05
    Registry
    NCT06949033

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesGuangzhou, Lanzhou

  4. Recruiting
    Feasibility of Enhanced Recovery After Surgery Without Prophylactic Abdominal Drainage Tubes After Laparoscopic Distal Gastrectomy For Gastric Cancer
    Phase
    Phase 3
    Started
    2025-06
    Registry
    NCT07029269

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesFuzhou, Guangzhou, Hangzhou, Lanzhou, Xi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImmunotherapy & targeted drugsImaging & AISurgery
Departments in papersSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatologyRadiology / nuclear medicineMedical oncology
Papers it led108
  1. The snoRNA SNORA21 promotes gastric tumorigenesis by attenuating P53 activity through CHK1 phosphorylation inhibition and PERP-dependent feedback loops.2026Cellular signalling
  2. TMEM176A drives anti-apoptotic signaling through TGM2-mediated ERK activation in gastric cancer.2026International immunopharmacology
  3. The Value of Double Contrast-Enhanced Ultrasonography in the Differential Diagnosis of Gastric Submucosal Tumors and the Assessment of the Malignant Risk of Gastrointestinal Stromal Tumors.2026Seminars in ultrasound, CT, and MR
  4. Targeted Dual-Responsive Liposomes Co-Deliver Jolkinolide B and Ce6 to Synergistically Enhance the Photodynamic/Immunotherapy Efficacy in Gastric Cancer through the PANoptosis Pathway.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  5. Identification and prioritization of high-frequency biomarkers and therapeutic targets in gastric cancer trials.2025BMC cancerFree full text
  6. KLC3 drives gastric cancer progression by stabilizing SLC2A5 to activate MAPK signaling and promote epithelial-mesenchymal transition.2025BMC cancerFree full text
  7. Identification of multiomics and immune infiltration-associated biomarkers for early gastric cancer: a machine learning-based diagnostic model development study.2025BMC cancerFree full text
  8. Indocyanine Green-Labeled Antibody-NOTCH2 as a New Fluorescent Molecular Imaging Probe for Gastric Cancer.2025Bioconjugate chemistryFree full text
  9. Comparing Quality of Life for Billroth II With Braun Versus Uncut Roux-en-Y Reconstruction After Total Laparoscopic Distal Gastrectomy for Gastric Cancer: A Randomized Clinical Trial.2025Cancer control : journal of the Moffitt Cancer CenterRCTFree full text
  10. The Black Hole of Immune Checkpoint Blocking Therapy for Gastric Cancer: Hyperprogressive Disease.2025Cancer scienceFree full text
  11. ULBP2 CAR-T cells enhance gastric cancer immunotherapy by inhibiting CAF activation.2025Cell death & diseaseFree full text
  12. Identification and Validation of a Novel Prognostic Signature of Gastric Cancer Based on Seven Complement System-Related Genes: An Integrated Analysis.2025Critical reviews in eukaryotic gene expression
  13. Integrative Analysis Reveals Differential Characteristics of DDR1 Mutant and Wild-type Gastric Cancers and Constructs their Prediction Models.2025Current medicinal chemistry
  14. Evolving Landscape of HER2-Targeted Therapies for Gastric Cancer Patients.2025Current treatment options in oncology
  15. Association between different patterns of obesity and the short-term outcomes of gastric cancer surgery.2025European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)Free full text
  16. Nutritional status of early oral feeding for gastric cancer patients after laparoscopic total gastrectomy: A retrospective cohort study.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  17. Sequential HIPEC, Claudin18.2-targeted therapy, and CapeOx chemotherapy leading to resolution of peritoneal metastases and curative resection in gastric cancer: a case report and literature review.2025Frontiers in immunologyFree full text
  18. Deep learning and multi-omics reveal programmed cell death-associated diagnostic signatures and prognostic biomarkers in gastric cancer.2025Frontiers in immunologyFree full text
  19. Renal capsule patient-derived xenograft model for gastric cancer: establishment and MRI characterization.2025Frontiers in immunologyFree full text
  20. Targeting the BAG2/CHIP axis promotes gastric cancer apoptosis by blocking apoptosome assembly.2025Frontiers in immunologyFree full text
  21. HER2-positive gastric cancer: from targeted therapy to CAR-T cell therapy.2025Frontiers in immunologyFree full text
  22. Targeting Eg5 using Arry520 combats gastric cancer by inducing monopolar spindles.2025Gene
  23. Multi-omic analysis reveals the role of coagulation factor family genes and their predictive value for immune checkpoint inhibitors efficacy in gastric cancer.2025International journal of biological macromolecules
  24. Does ambient particulate matter 1 increase the risk of gastric cancer in the northwest of China?2025International journal of cancer
  25. Clinical application value of modified overlap anastomosis for Siewert type II and III adenocarcinoma of esophagogastric junction.2025Journal of cancer research and clinical oncologyFree full text
  26. Gastric cancer-derived exosomal let-7 g-5p mediated by SERPINE1 promotes macrophage M2 polarization and gastric cancer progression.2025Journal of experimental & clinical cancer research : CRFree full text
  27. Targeted DDR1 Treatment Strategy Enhances PD-1 Immunotherapy Efficacy against Gastric Cancer.2025Journal of medicinal chemistryFree full text
  28. Single-cell RNA sequencing and spatial transcriptomics reveal the heterogeneity and intercellular communication of cancer-associated fibroblasts in gastric cancer.2025Journal of translational medicineFree full text
  29. Neoadjuvant cadonilimab plus FLOT chemotherapy in locally advanced gastric/gastroesophageal junction adenocarcinoma: A multicenter, phase 2 study.2025Med (New York, N.Y.)
  30. Effect of PRKD3 on cell cycle in gastric cancer progression and downstream regulatory networks.2025Medical oncology (Northwood, London, England)
  31. Nanomaterials in gastric cancer: pioneering precision medicine for diagnosis, therapy, and prevention.2025Medical oncology (Northwood, London, England)
  32. ELK1 modulates SF3B3 transcriptional activity to stimulate proliferation and inhibit apoptosis in gastric cancer through the activation of the MAPK pathway.2025Neoplasma
  33. The impact of GST genetic polymorphisms on the response to oxaliplatin-based chemotherapy and survival prognosis in gastric cancer patients.2025Pharmacogenomics
  34. The expression of transmembrane channel-like 5 in gastric cancer and its impact on tumor progression.2025Scientific reportsFree full text
  35. SERPINE1 Facilitates Metastasis in Gastric Cancer Through Anoikis Resistance and Tumor Microenvironment Remodeling.2025Small (Weinheim an der Bergstrasse, Germany)
  36. A prospective and comparative study on improving the diagnostic accuracy of early gastric cancer based on deep convolutional neural network real-time diagnosis system (with video).2025Surgical endoscopy
  37. The role of TMEM119 in gastric adenocarcinoma and its specific effects on immunity.2025The Journal of international medical researchFree full text
  38. A case of neonatal gastric teratoma complicated with occult gastrointestinal hemorrhage misdiagnosed as lymphangioma.2025The Turkish journal of pediatrics
  39. The current landscape and advances in functional-preserving gastric cancer surgery.2025World journal of surgical oncologyFree full text
  40. Historical evolution and current research status of lymph node staging in gastric cancer: a review.2025World journal of surgical oncologyFree full text
  41. eIF6: a promising therapeutic target for gastric carcinoma via PI3K/AKT pathway modulation.2025World journal of surgical oncologyFree full text
  42. Combination of clinical and spectral-CT iodine concentration for predicting liver metastasis in gastric cancer: a preliminary study.2024Abdominal radiology (New York)
  43. Correlation of CT parameters and PD-L1 expression status in gastric cancer.2024Abdominal radiology (New York)
  44. Not all carotenoids can reduce the risk of gastric cancer: a systematic review with meta-analysis.2024BMC gastroenterologyFree full text
  45. Exploring the therapeutic potential of diterpenes in gastric cancer: Mechanisms, efficacy, and clinical prospects.2024Biomolecules & biomedicineFree full text
  46. Prediction of Ki-67 expression in gastric gastrointestinal stromal tumors using histogram analysis of monochromatic and iodine images derived from spectral CT.2024Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  47. Targeting NUF2 suppresses gastric cancer progression through G2/M phase arrest and apoptosis induction.2024Chinese medical journalFree full text
  48. Current status of neoadjuvant immunotherapy for the treatment of gastric cancer.2024Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  49. The application of organoids in cancers associated with pathogenic infections.2024Clinical and experimental medicineFree full text
  50. Whether the use of intravenous contrast-enhanced ultrasound can improve the accuracy of T stage diagnosis of gastric cancer?2024Clinical hemorheology and microcirculation
  51. Value of spectral CT parameters in predicting the efficacy of neoadjuvant chemotherapy for gastric cancer.2024Clinical radiology
  52. Prognostic Value and Therapeutic Significance of CCL Chemokines in Gastric Cancer.2024Current medicinal chemistry
  53. Mesenchymal Stem Cells Target Gastric Cancer and Deliver Epirubicin via Tunneling Nanotubes for Enhanced Chemotherapy.2024Current stem cell research & therapy
  54. IL-17A in gastric carcinogenesis: good or bad?2024Frontiers in immunologyFree full text
  55. SOX combined with apatinib and camrelizumab in the treatment of resectable locally advanced gastric cancer: a case report.2024Frontiers in immunologyFree full text
  56. UBE2L3 expression in human gastric cancer and its clinical significance.2024Journal of cancer research and clinical oncologyFree full text
  57. High expression of NOTCH2 in gastric adenocarcinoma: A novel early diagnostic target.2024Journal of gastroenterology and hepatology
  58. Biological Clock Genes are Crucial and Promising Biomarkers for the Therapeutic Targets and Prognostic Assessment in Gastric Cancer.2024Journal of gastrointestinal cancer
  59. MicroRNAs in Helicobacter pylori-infected gastric cancer: Function and clinical application.2024Pharmacological research
  60. Photodynamic therapy may salvage chemotherapy failure in gastric cancer: A case report and a literature review.2024Photodiagnosis and photodynamic therapy
  61. EGCG targeting STAT3 transcriptionally represses PLXNC1 to inhibit M2 polarization mediated by gastric cancer cell-derived exosomal miR-92b-5p.2024Phytomedicine : international journal of phytotherapy and phytopharmacology
  62. Imaging advances in efficacy assessment of gastric cancer neoadjuvant chemotherapy.2023Abdominal radiology (New York)
  63. Risk of venous thromboembolism in patients undergoing gastric cancer surgery: a systematic review and meta-analysis.2023BMC cancerFree full text
  64. Glycosyltransferase GLT8D1 and GLT8D2 serve as potential prognostic biomarkers correlated with Tumor Immunity in Gastric Cancer.2023BMC medical genomicsFree full text
  65. Organoids: Construction and Application in Gastric Cancer.2023BiomoleculesFree full text
  66. PICH Activates Cyclin A1 Transcription to Drive S-Phase Progression and Chemoresistance in Gastric Cancer.2023Cancer research
  67. A novel adenosine signalling-based prognostic signature in gastric cancer and its association with cancer immune features and immunotherapy response.2023Cell biology international
  68. A nine-gene signature as prognostic biomarker in gastric cancer by bioinformatics analysis.2023Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  69. Combined Inhibition of KIF11 and KIF15 as an Effective Therapeutic Strategy for Gastric Cancer.2023Current cancer drug targets
  70. Focusing on Helicobacter pylori infection in the elderly.2023Frontiers in cellular and infection microbiologyFree full text
  71. Photodynamic therapy improves the outcome of immune checkpoint inhibitors via remodelling anti-tumour immunity in patients with gastric cancer.2023Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  72. Epidemiology, risk areas and macro determinants of gastric cancer: a study based on geospatial analysis.2023International journal of health geographicsFree full text
  73. Exploration of gastric carcinogenesis from the relationship between bile acids and intestinal metaplasia and intragastric microorganisms (H. pylori and non-H. pylori).2023Journal of cancer research and clinical oncologyFree full text
  74. A practical recurrence risk model based on Lasso-Cox regression for gastric cancer.2023Journal of cancer research and clinical oncologyFree full text
  75. STAT1 suppresses the transcriptional activity of TRIM21 in gastric cancer.2023Journal of cancer research and clinical oncologyFree full text
  76. Predictive value of 18F-FDG PET/CT multi-metabolic parameters and tumor metabolic heterogeneity in the prognosis of gastric cancer.2023Journal of cancer research and clinical oncologyFree full text
  77. The prognostic value of FAR and a novel FAR-CA125 score in resectable gastric signet ring cell carcinoma patients.2023Journal of cancer research and clinical oncologyFree full text
  78. Exploring the role of PMEPA1 in gastric cancer.2023Molecular and cellular probes
  79. Exploring the role of FBXO5 in gastric cancer.2023Molecular and cellular probes
  80. High expression of TMEM200A is associated with a poor prognosis and immune infiltration in gastric cancer.2023Pathology oncology research : PORFree full text
  81. Research progress of potential factors influencing photodynamic therapy for gastrointestinal cancer.2023Photodiagnosis and photodynamic therapy
  82. MKRN2 inhibits the proliferation of gastric cancer by downregulating PKM2.2022AgingFree full text
  83. Identification of differentially expressed miRNAs derived from serum exosomes associated with gastric cancer by microarray analysis.2022Clinica chimica acta; international journal of clinical chemistry
  84. Combination of clinical and spectral-CT parameters for predicting lymphovascular and perineural invasion in gastric cancer.2022Diagnostic and interventional imaging
  85. Meta-Analysis of Efficacy and Safety of Karelizumab Combined with Apatinib in the Treatment of Advanced Gastric Cancer.2022Disease markersFree full text
  86. The N6-methyladenosine:mechanisms, diagnostic value, immunotherapy prospec-ts and challenges in gastric cancer.2022Experimental cell research
  87. MCEMP1 is a potential therapeutic biomarker associated with immune infiltration in advanced gastric cancer microenvironment.2022Gene
  88. TCF7L2 promotes anoikis resistance and metastasis of gastric cancer by transcriptionally activating PLAUR.2022International journal of biological sciencesFree full text
  89. Measurement of soluble PD-1 and soluble PD-L1 as well as PD-L1 and PD-1 from perioperative patients with gastric carcinoma.2022Japanese journal of clinical oncology
  90. Long non-coding RNA TNK2 AS1/microRNA-125a-5p axis promotes tumor growth and modulated phosphatidylinositol 3 kinase/AKT pathway.2022Journal of gastroenterology and hepatology
  91. NCAPH regulates gastric cancer progression through DNA damage response.2022Neoplasma
  92. Photodynamic Therapy in Combination with Chemotherapy, Targeted, and Immunotherapy As a Successful Therapeutic Approach for Advanced Gastric Adenocarcinoma: A Case Report and Literature Review.2022Photobiomodulation, photomedicine, and laser surgery
  93. Therapeutic strategies targeting uPAR potentiate anti-PD-1 efficacy in diffuse-type gastric cancer.2022Science advancesFree full text
  94. Clinico-radiological nomogram for preoperatively predicting post-resection hepatic metastasis in patients with gastric adenocarcinoma.2022The British journal of radiologyRCTFree full text
  95. Single-cell landscape reveals active cell subtypes and their interaction in the tumor microenvironment of gastric cancer.2022TheranosticsFree full text
  96. Study on the expression of c-Met in gastric cancer and its correlation with preoperative serum tumor markers and prognosis.2022World journal of surgical oncologyFree full text
  97. Immune Cell Landscape in Gastric Cancer.2021BioMed research internationalFree full text
  98. Long intergenic noncoding RNA00265 promotes proliferation of gastric cancer via the microRNA-144-3p/Chromobox 4 axis.2021BioengineeredFree full text
  99. Prognostic Value of lncRNA PVT1 for Patients with Gastric Cancer: A Meta-Analysis.2021Disease markersFree full text
  100. Construction and Validation of a Novel Prognostic Signature for Intestinal Type of Gastric Cancer.2021Disease markersFree full text
  101. Auditory and Visual Stimulation for Abdominal Postoperative Patients Experiencing Enhanced Recovery After Surgery (ERAS).2021Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and AssociatesRCT
  102. Prognostic Value of Combination of Inflammatory and Tumor Markers in Resectable Gastric Cancer.2021Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  103. Damage Control Surgery Saves Patient with Gastric Lymphoma from Radical Gastrectomy.2021Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  104. Carcinosarcoma and sarcomatoid carcinoma of the stomach: Two case reports.2021MedicineFree full text
  105. Hyperactivation of HER2-SHCBP1-PLK1 axis promotes tumor cell mitosis and impairs trastuzumab sensitivity to gastric cancer.2021Nature communicationsFree full text
  106. A novel UBE2T inhibitor suppresses Wnt/β-catenin signaling hyperactivation and gastric cancer progression by blocking RACK1 ubiquitination.2021OncogeneFree full text
  107. Construction of PD1/CD28 chimeric-switch receptor enhances anti-tumor ability of c-Met CAR-T in gastric cancer.2021OncoimmunologyFree full text
  108. Evidence Mapping of Proton Therapy, Heavy Ion Therapy, and Helical Tomotherapy for Gastric Cancer.2021Oncology research and treatment
Chinese-language papers (not in the count)3
  1. Research progress in effects of MAGE-A family on gastric cancer.2023Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
  2. [Correlations of 18F-FDG PET/CT Metabolic Parameters and Metabolic Heterogeneity with Human Epidermal Growth Factor Receptor 2 Expression in Patients with Gastric Cancer].2022Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  3. [Spectral CT multi-parameter imaging in preoperatively evaluation the status of lymphovascular and perineural invasion of gastric cancer].2022Zhonghua yi xue za zhi
All its trials on ClinicalTrials.gov, any status14
  1. Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction CancerRecruitingNCT06731478Study sitePhase 3Start 2025-02
  2. Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction AdenocarcinomaRecruitingNCT06949033Study sitePhase 3Start 2025-05
  3. Feasibility of Enhanced Recovery After Surgery Without Prophylactic Abdominal Drainage Tubes After Laparoscopic Distal Gastrectomy For Gastric CancerRecruitingNCT07029269Study sitePhase 3Start 2025-06
  4. Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction AdenocarcinomaRecruitingNCT06925243Study sitePhase 3Start 2025-04
  5. A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in ChinaStatus unknownNCT05638269Study siteStart 2022-03
  6. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionCompletedNCT05052801Study sitePhase 3Start 2022-03
  7. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.TerminatedNCT05111626Study sitePhase 3Start 2022-03
  8. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric CancerActive, not recruitingNCT05180734Study sitePhase 3Start 2022-02
  9. A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-OverexpressionStatus unknownNCT04714190Study sitePhase 3Start 2021-03
  10. A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Gastric CarcinomaTerminatedNCT04718402Study sitePhase 1Start 2021-03
  11. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901CompletedNCT04805307Study sitePhase 1Start 2020-12
  12. Comparing the Prognosis of Patients With Cardia and Non-cardia Gastric Cancer.Status unknownNCT03895008Study siteStart 2019-07
  13. Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric CancerActive, not recruitingNCT04208347Study sitePhase 2/Phase 3Start 2019-12
  14. Dendritic Cell-based Immunotherapy in Treatment Gastric CancerStatus unknownNCT03410732Study sitePhase 2Start 2017-07

Run the PubMed searchClinicalTrials.gov

Cancer

Chordoma

脊索瘤

Led 1 of the 105 English-language PubMed papers on chordoma with an author in mainland China, 2021–2025: 0.9%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

2 hospitals in Lanzhou for chordoma88 hospitals in China for chordoma

No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurosurgery

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 15 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
15
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 5520222023: 2220232024: 3320242025: 332025

8 hospitals in Lanzhou for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicinePathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led15
  1. Long non-coding RNA BCAR4 regulates osteosarcoma progression by targeting microRNA-1260a.2025Bulletin du cancer
  2. Thermo-responsive nano-hydrogel-based delivery of Saikosaponin a to enhance anti-PD-1 therapy in osteosarcoma.2025Nanomedicine (London, England)
  3. PDK1, associated with glycolytic metabolism, is a potential prognostic biomarker in osteosarcoma.2025PloS one
  4. The Role of Ubiquitination in Osteosarcoma Development and Therapies.2024Biomolecules
  5. Ferroptosis defense mechanisms: The future and hope for treating osteosarcoma.2024Cell biochemistry and function
  6. Circ_0004674 regulation of glycolysis and proliferation mechanism of osteosarcoma through miR-140-3p/TCF4 pathway.2024Journal of biochemical and molecular toxicology
  7. Silencing circular RNA hsa_circABCC1 inhibits osteosarcoma progression through down-regulating HDAC4 via sponging miR-591.2023Environmental toxicology
  8. Research Progress of Nanomaterials in Chemotherapy of Osteosarcoma.2023Orthopaedic surgery
  9. The value of Ki-67 as a prognostic biomarker in osteosarcoma: A systematic review and meta-analysis.2022Asian journal of surgery
  10. Extraosseous Ewing's sarcoma/peripheral primitive neuroectodermal tumour of the kidney: a case report and literature review.2022BMC urology
  11. Roles of MET in human cancer.2022Clinica chimica acta; international journal of clinical chemistry
  12. KMT5A Knockdown Suppresses Osteosarcoma Cell Proliferation and Metastasis Through Ꞵ-Catenin Signalling.2022Clinical and investigative medicine. Medecine clinique et experimentale
  13. TRIP13 knockdown inhibits the proliferation, migration, invasion, and promotes apoptosis by suppressing PI3K/AKT signaling pathway in U2OS cells.2022Molecular biology reports
  14. Comparative analysis of magnetic resonance imaging and pathological findings of microcystic meningioma and meningeal Ewing sarcoma/peripheral primitive neuroectodermal tumors.2021Acta neurologica Belgica
  15. Exosomal miR-21-5p derived from bone marrow mesenchymal stem cells promote osteosarcoma cell proliferation and invasion by targeting PIK3R1.2021Journal of cellular and molecular medicine
Earlier papers (2016–2020)9
  1. Sphingosine kinase 1 contributes to doxorubicin resistance and glycolysis in osteosarcoma.2020Molecular medicine reports
  2. Silencing of RIPK4 inhibits epithelial‑mesenchymal transition by inactivating the Wnt/β‑catenin signaling pathway in osteosarcoma.2020Molecular medicine reports
  3. Rosmarinic acid exerts an anticancer effect on osteosarcoma cells by inhibiting DJ-1 via regulation of the PTEN-PI3K-Akt signaling pathway.2020Phytomedicine : international journal of phytotherapy and phytopharmacology
  4. HOXA5 overexpression promotes osteosarcoma cell apoptosis through the p53 and p38α MAPK pathway.2019Gene
  5. COX‑2 promotes epithelial‑mesenchymal transition and migration in osteosarcoma MG‑63 cells via PI3K/AKT/NF‑κB signaling.2019Molecular medicine reports
  6. WNT5A promotes migration and invasion of human osteosarcoma cells via SRC/ERK/MMP-14 pathway.2018Cell biology international
  7. Pelargonidin induces antitumor effects in human osteosarcoma cells via autophagy induction, loss of mitochondrial membrane potential, G2/M cell cycle arrest and downregulation of PI3K/AKT signalling pathway.2018Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  8. Exosomes Derived from Human Bone Marrow Mesenchymal Stem Cells Promote Tumor Growth Through Hedgehog Signaling Pathway.2017Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
  9. Long Noncoding RNA GAS5 Suppresses Cell Growth and Epithelial-Mesenchymal Transition in Osteosarcoma by Regulating the miR-221/ARHI Pathway.2017Journal of cellular biochemistry

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 5 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 1.0%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 2220242025: 112025

3 hospitals in Lanzhou for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicineSurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 2 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

1 hospital in Lanzhou for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 2 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 1.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

4 hospitals in Lanzhou for Ewing sarcoma139 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 12 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.7%.

Papers led
12
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 2220232024: 2220242025: 442025

3 hospitals in Lanzhou for multiple myeloma178 hospitals in China for multiple myeloma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-06
    Registry
    NCT07569757

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengde, Chengdu, Chongqing, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Xi'an, Xuzhou, Zhanjiang, Zhengzhou, Zhuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDiagnosis, MRD & riskBispecific & antibody drugs
Departments in papersRadiology / nuclear medicinePathology / laboratory medicineMedical oncologyGastroenterology / hepatology
Papers it led12
  1. Analysis of discordant results in multi-technique platform-based MRD detection in multiple myeloma and the clinical decision-making dilemma.2026Leukemia & lymphoma
  2. Magnetic resonance imaging-based nomograms predict high-risk cytogenetic abnormalities in multiple myeloma: a two-centre study.2025Clinical radiology
  3. Efficacy and Safety of triplet versus doublet regimens in patients with multiple myeloma: A systematic review and meta-analysis.2025Current problems in cancer
  4. Threonine and tyrosine kinase promotes multiple myeloma progression by regulating regucalcin expression.2025Experimental cell research
  5. Peroxiredoxins as novel indicators in multiple myeloma associated with ferroptosis and immune infiltration.2025Scientific reportsFree full text
  6. Construction of the prediction model for multiple myeloma based on machine learning.2024International journal of laboratory hematology
  7. Elevated programmed cell death-1 protein/ligand (PD-1/PD-L1) and variants are associated with susceptibility to multiple myeloma: a case-control study in the Chinese cohort.2024Nucleosides, nucleotides & nucleic acids
  8. LGR4 promotes tumorigenesis by activating TGF-β1/Smad signaling pathway in multiple myeloma.2023Cellular signalling
  9. Obesity as a risk factor for multiple myeloma: insight on the role of adipokines.2023Pathology oncology research : PORFree full text
  10. The yin-yang effects of immunity: From monoclonal gammopathy of undetermined significance to multiple myeloma.2022Frontiers in immunologyFree full text
  11. Nontargeted and targeted metabolomics approaches reveal the key amino acid alterations involved in multiple myeloma.2022PeerJFree full text
  12. Efficacy and safety of daratumumab in the treatment of multiple myeloma: a systematic review and meta-analysis.2021The Journal of international medical researchFree full text
Chinese-language papers (not in the count)6
  1. [Prognosis and immune biomarkers of multiple myeloma].2024Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
  2. [Prognostic Value of A New Risk Stratification Model (R2-ISS) in Newly Diagnosed Multiple Myeloma].2022Zhongguo shi yan xue ye xue za zhi
  3. [A Prognostic Nomogram Based on Response to Bortezomib and BTK Expression for Treatment-Experienced Multiple Myeloma Patients].2022Zhongguo shi yan xue ye xue za zhi
  4. [Clinical Significance of sFLC/MP Level and Light Chain Escape in Patients with Multiple Myeloma Relapse].2021Zhongguo shi yan xue ye xue za zhi
  5. [The Influence of CONUT Score on the Prognosis of Patients with Multiple Myeloma].2021Zhongguo shi yan xue ye xue za zhi
  6. [Multiple myeloma with multiple extramedullary lesions of pancreas, stomach and skin: a case report].2021Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
All its trials on ClinicalTrials.gov, any status2
  1. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07569757Study sitePhase 3Start 2026-06
  2. TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT03952091Study sitePhase 3Start 2019-03

Run the PubMed searchClinicalTrials.gov

Other diseases

IgG4-related disease

IgG4相关性疾病

Led 2 of the 246 English-language PubMed papers on IgG4-related disease with an author in mainland China, 2021–2025: 0.8%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025

1 hospital in Lanzhou for IgG4-related disease46 hospitals in China for IgG4-related disease

No open trial on IgG4-related disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesDiagnosis & look-alikesKidney, retroperitoneum & vesselsTreatment & relapse

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 2 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 0.4%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

1 hospital in Lanzhou for myasthenia gravis93 hospitals in China for myasthenia gravis

No open trial on myasthenia gravis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesPregnancy, children, older adults
Departments in papersNeurology
Papers it led2
  1. Autoimmune polyendocrine syndrome type 2 in children: a case report and literature review.2025BMC pediatricsFree full text
  2. Wernicke encephalopathy, myasthenia gravis, or both?2022Panminerva medica
All its trials on ClinicalTrials.gov, any status1
  1. Study of Telitacicept in Generalized Myasthenia GravisCompletedNCT05737160Study sitePhase 3Start 2023-03

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led 2 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 0.8%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 0020242025: 002025

1 hospital in Lanzhou for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurologyPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led no English-language PubMed papers on Takayasu arteritis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Lanzhou for Takayasu arteritis108 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology
Chinese-language papers (not in the count)1
  1. [A case of Takayasu arteritis complicated with cavernous sinus syndrome presenting as unilateral optic nerve DWI hyperintensity].2024[Zhonghua yan ke za zhi] Chinese journal of ophthalmology

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led no English-language PubMed papers on idiopathic pulmonary fibrosis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Lanzhou for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. [Progress in sleep-disordered breathing in idiopathic pulmonary fibrosis].2017Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led 1 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 0.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

2 hospitals in Lanzhou for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 2 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.3%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

3 hospitals in Lanzhou for IgA nephropathy346 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Gaucher disease

戈谢病

Led no English-language PubMed papers on Gaucher disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Lanzhou for Gaucher disease41 hospitals in China for Gaucher disease

No open trial on Gaucher disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher DiseaseCompletedNCT05529992Study sitePhase 3Start 2023-01

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led no English-language PubMed papers on primary biliary cholangitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

1 hospital in Lanzhou for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis
    Phase
    Phase 3
    Started
    2023-02
    Registry
    NCT05751967

    Age 18 years to 75 years (registered criteria)

    Led by Xijing Hospital; 6 listed hospitals as study sitesChengdu, Guangzhou, Lanzhou, Nanjing, Shenyang, Tianjin, Xi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status2
  1. Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary CholangitisRecruitingNCT05751967Study sitePhase 3Start 2023-02
  2. Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary CholangitisActive, not recruitingNCT06174402Study sitePhase 2/Phase 3Start 2023-08

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary sclerosing cholangitis

原发性硬化性胆管炎

Led 1 of the 100 English-language PubMed papers on primary sclerosing cholangitis with an author in mainland China, 2021–2025: 1.0%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

2 hospitals in Lanzhou for primary sclerosing cholangitis90 hospitals in China for primary sclerosing cholangitis

No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

兰州大学第二医院

Lanzhou University Second Hospital

兰州

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look at the hospital's own pages linked above.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Second Hospital of Lanzhou University; Lanzhou University Second hospital; Xigu Branch of the Second Hospital of Lanzhou University; Lanzhou University Second Clinical Medical College

Suggest a correctionDownload the data